Earnings ·
Harmony Biosciences Holdings, Inc. reported second-quarter 2026 financial results on August 4, 2026
HRMYHarmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. reported second-quarter 2026 financial results on August 4, 2026. Net product revenue for WAKIX reached $261.3 million, a 30% increase year-over-year, driven by an estimated average patient count of 8,950. The company reaffirmed its full-year net revenue guidance of $1.0 billion to $1.04 billion. Net income was $75.4 million, or $1.28 per diluted share, compared to $39.8 million in the prior year period. Operating expenses decreased 5% to $108.8 million due to lower R&D and G&A costs relative to prior-year charges. The company also announced encouraging Phase 1 single ascending dose data for its orexin-2 agonist BP-205, highlighting favorable pharmacokinetic profiles and safety. Harmony maintains a strong liquidity position of $962.5 million in cash, cash equivalents, and investments as of June 30, 2026. The company operates in the pharmaceutical industry, developing and commercializing therapies for rare neurological diseases.